While
sequencing
a whole genome
at $100 may be
possible in the
next few years,
interpreting the
data remains
a million dollar
problem and
Strand has
made significant
strides towards
reducing the post-
sequencing cost of
testing.
diagnostics side. Over the
years, one has either seen
consolidation of these
companies to include
these under the same
umbrella via aggregation.
With the Indian talent
pool being trained across
the best universities in
India and globally, we
are able to build products
and services that are
benchmarked against the
world’s best at affordable
cost. It is only a question
of time when these will
be leveraged across the
huge domestic market
and also across the globe.
This is the scenario we
foresee across Strand Life
Science’s products.
Markets will also see
closer collaborations
between biotech
and pharmaceutical
companies to offer
more comprehensive
treatment options.
The biotech industry
still requires significant
research and innovation
in varied areas. The
investment ecosystem
still continues to
support IT and other
online industries, partly
because of lack of depth
and understanding of
the unique funding
requirements of
the biotechnology
industry and also
the need for higher
investments to fund
continuous development.
The regulatory landscape
of the industry swings
between extreme
regulatory environments
in some areas and no
regulation at all in others
like for example genetic
testing. Government
thinking and policies in
this direction would create
larger adaptability.
In certain areas, a
large number of me-
too companies exist.
These companies are
offering varied levels of
quality of product and
service. Over a couple
of years there would
be consolidation or a
market shake out is
likely, as can already
be observed in the
US market.
BIOVOICENEWS.COM
39